Showing results (2441-2450 of 2,573) with videos related to
Sort By:
Pageof 258
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.American Journal of Human Genetics|May 21, 2019
Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington DiseaseGalen E B Wright, Jennifer A Collins, Chris Kay, et al.Kidney360|April 4, 2022
Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney InjuryKelly R McMahon, Hayton Chui, Shahrad Rod Rassekh, et al.Cancer|October 3, 2014
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation ConsortiumLiza C Villaruz, Mark A Socinski, Shira Abberbock, et al.Lung Cancer (Amsterdam, Netherlands)|March 14, 2025
A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancerByoung Chul Cho, Melissa Johnson, Jair Bar, et al.Journal of the American Society of Nephrology : JASN|July 12, 2014
Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell linesLijun Ma, Gregory S Shelness, James A Snipes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2018
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical TrialsD Ross Camidge, Dong-Wan Kim, Marcello Tiseo, et al.Nature Genetics|August 4, 2015
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancerFolefac Aminkeng, Amit P Bhavsar, Henk Visscher, et al.Pediatric Nephrology (Berlin, Germany)|October 19, 2022
Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational studyKelly R McMahon, Asaf Lebel, Shahrad Rod Rassekh, et al.Cancers|January 11, 2024
First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid TumorsAnna R Schreiber, Jodi A Kagihara, Bradley R Corr, et al.Pageof 258